草分枝杆菌F.U.36治疗支气管哮喘的临床研究  

The clinical research of mycobacterium phlei F.U.36 for bronchical asthma

作　　者：韦中盛[1] 黄达[1] 韦英群[2] 唐任光[3] 

机构地区：[1]右江民族医学院附属医院内科,广西百色533000 [2]右江民族医学院附属医院病理科,广西百色533000 [3]右江民族医学院附属医院检验科,广西百色533000

出　　处：《华夏医学》2004年第6期877-880,共4页Acta Medicinae Sinica

摘　　要：目的 :研究草分枝杆菌 F.U.36 (乌体林斯注射液 )治疗支气管哮喘患者的疗效及其对免疫指标的影响。方法 :将80例非急性发作期哮喘患者随机分为 2组 ,观察组与对照组各 4 0例 ,两组在维持原控制用药的基础上 ,观察组加用乌体林斯注射液 1.72 μg肌肉注射 ,开始肌肉注射 1次 /周 ,2个月以后肌肉注射 1次 / 4周 ,疗程 1年 ,对照组维持原来治疗。治疗前后分别观察临床症状及进行免疫指标检测 ,1年后评价疗效并进行统计学分析。结果 :观察组临床控制 8例 ,显效 2 0例 ,好转 11例 ,无效 1例 ,总有效率为 97.5 % ;对照组临床控制 2例 ,显效 15例 ,好转 15例 ,无效 8例 ,总有效率为 80 .0 %。两组总有效率相比差异有显著性 (P<0 .0 5 )。观察组治疗后每天吸入布地奈德的剂量较对照组明显减少 (P<0 .0 1) ,差异有高度显著性。Ig G、Ig A、CD3、CD8、IFN- γ均升高 (P<0 . 0 1) ,Ig E、Ig M、CD4 、CD4 / CD8、IL- 4均降低 (P<0 . 0 1) ;对照组治疗前后上述指标变化则不明显。结论 :在常规治疗用药的基础上配合草分枝杆菌 F.U. 36免疫治疗 ,可以明显改善哮喘患者的临床症状 ,减少发作 ,草分枝杆菌 F.U. 36是一种有效的免疫调节剂 ,能改善细胞免疫及体液免疫功能 ,调节 Th1/ Th2的平衡 ,具有治疗支气管哮喘的作用。Objective:To study the curative effect and the influence to its immune target of mycobacterium phlei F.U.36 (Utilin“S”) for bronchial asthma.Methods:80 patients with asthma were divided into two groups randomly,treatment group with comparison group with different 40 instances.In addition to maintenance treatment,the observation group acceded to im. With mycobacterium phlei F.U.36 1.72μg,beginning each week im.1 time,2 months later per four weeks im. 1 time,period of treatment was 1 year,compared with the clinical features and check the immune target around the treatment,1 year later appraise the curative effect and carried out statistical analysis.Results:the observation group,clinical control 8 instances,produce effects 20 instances,11 instances look up,1 instance invalidates,total valid ratio was 97.5%;the comparison group,clinical control 2 instances,produce effects 15 instances,15 instances look up,8 instances invalidate,total valid ratio is 80.0%.The difference of total valid ratio between these two groups was markedness(P<0.05).After treat the dosage of which the treatment group imbile Budesonide each day was less than that of the other group,the difference between them was height markedness.IgG、 IgA 、CD 3、 CD 8、 IFN-γ all ascends(P<0.01),IgE、 IgM、 CD 4 、CD 4/CD 8、IL-4 all cut down(P<0.01);The above-mentionde target changes unobviously about the comparison group treats.Conclusion:On the base of routine cure usage cooperate with the immune cure by mycobacterium phlei F.U.36,which can improve the clinical symptoms of asthma sufferer obviously and induce paroxysm. Mycobacterium phlei F.U.36 is an effentive immune-modulation,could improve the function of cell immunity and sap immunity,could adjust the balance of Th1/Th2 and treat asthma.

关 键 词：草分枝杆菌 支气管哮喘 免疫治疗 

分 类 号：R562.25[医药卫生—呼吸系统] R392-33[医药卫生—内科学]